⌘+K

Pulse Explore Communities Researchers Journals

Home Communities Explore

July 15, 2025

Supplementary Figure 3 from The XPO1 Inhibitor Eltanexor Modulates the Wnt/β-Catenin Signaling Pathway to Reduce Colorectal Cancer Tumorigenesis

Andrew E. Evans Sahida Afroz Alexa Magstadt Anup Kasi Dan A. Dixon

View at Publisher

Ask AI

Bookmark

Share

Key Points

Eltanexor, an xpo1 inhibitor, effectively reduces tumor growth in colorectal cancer xenograft models.
The treatment demonstrates modulation of the wnt/beta-catenin signaling pathway crucial for tumorigenesis.
Research focused on the HCT116 xenograft model to assess the therapy's impact on growth rates.
These findings suggest that eltanexor could offer a novel approach in managing colorectal cancer.

No abstract yet

We only have this paper's title and publication details.

Read it at the source→

Implication

Eltanexor reduces tumorigenesis in colorectal cancer models by impacting the Wnt/beta-catenin signaling pathway, showing potential for treatment.

Abstract

Figure S3. Eltanexor treatment reduces HCT116 xenograft Growth.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Evans et al. (2025) studied this question.

synapsesocial.com/papers/689a02bce6551bb0af8cc728 https://doi.org/10.1158/2767-9764.29568704

View at Publisher

Ask AI

Bookmark

Share

Keep reading

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Supplementary Figure 4 from The XPO1 Inhibitor Eltanexor Modulates the Wnt/β-Catenin Signaling Pathway to Reduce Colorectal Cancer Tumorigenesis2025
2Supplementary Figure 2 from The XPO1 Inhibitor Eltanexor Modulates the Wnt/β-Catenin Signaling Pathway to Reduce Colorectal Cancer Tumorigenesis2025
3Supplementary Figure 5 from The XPO1 Inhibitor Eltanexor Modulates the Wnt/β-Catenin Signaling Pathway to Reduce Colorectal Cancer Tumorigenesis2025
4Supplementary Figure 1 from The XPO1 Inhibitor Eltanexor Modulates the Wnt/β-Catenin Signaling Pathway to Reduce Colorectal Cancer Tumorigenesis2025
5Figure 2 from The XPO1 Inhibitor Eltanexor Modulates the Wnt/β-Catenin Signaling Pathway to Reduce Colorectal Cancer Tumorigenesis2025

More related papers

Figure 3 from The XPO1 Inhibitor Eltanexor Modulates the Wnt/β-Catenin Signaling Pathway to Reduce Colorectal Cancer Tumorigenesis2025
Figure 6 from The XPO1 Inhibitor Eltanexor Modulates the Wnt/β-Catenin Signaling Pathway to Reduce Colorectal Cancer Tumorigenesis2025
Data from The XPO1 Inhibitor Eltanexor Modulates the Wnt/β-Catenin Signaling Pathway to Reduce Colorectal Cancer Tumorigenesis2025